Alzheimer's Disease variant portal (ADVP): a catalog of genetic findings for Alzheimer's Disease

Pavel P. Kuksa, PhD[1,2,*]; Chia-Lun Liu, PhD[1,2,*]; Wei Fu, PhD[1,2,*]; Liming Qu, MS[1,2]; Yi Zhao, MS[1,2]; Zivadin Katanic, BS[1,2]; Amanda B Kuzma, MS[1,2]; Pei-Chuan Ho, MS[4]; Kai-Teh Tzeng, MS[4]; Otto Valladares, BS[1,2]; Shin-Yi Chou, PhD[1,2,4]; Adam C Naj, PhD[1,3]; Gerard D Schellenberg, PhD[1,2]; Li-San Wang, PhD[1,2,^]; and Yuk Yee Leung, PhD[1,2,^]

[1]Penn Neurodegeneration Genomics Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia PA, USA

[2] Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia PA, USA

[3] Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia PA, USA

[4] Department of Economics, Lehigh University, Bethlehem, PA, USA

** co-first author*

^ co-corresponding author

Corresponding author information:

Li-San Wang, PhD.

Mailing address: Richards Building, D101, 3700 Hamilton Walk, Philadelphia, PA 19104

Phone: 215-746-7015

Fax: 215-573-3111

Email: lswang@pennmedicine.upenn.edu

Yuk Yee Leung, PhD.

Mailing address: Richards Building, D102, 3700 Hamilton Walk, Philadelphia, PA 19104

Phone: 215-573-3729

Fax: 215-573-3111

Email: yyee@pennmedicine.upenn.edu

Abstract

Alzheimer's Disease (AD) genetics has made substantial progress through genome-wide association studies (GWASs). An up-to-date resource providing harmonized, searchable information on AD genetic variants with linking to genes and supporting functional evidence is needed.

We developed the Alzheimer's Disease Variant Portal (ADVP), an extensive collection of associations curated from >200 GWAS publications from Alzheimer's Disease Genetics Consortium (ADGC) and other researchers. Publications are reviewed systematically to extract top associations for harmonization and genomic annotation.

ADVP V1.0 catalogs 6,990 associations with disease-risk, expression quantitative traits, endophenotypes and neuropathology across >900 loci, >1,800 variants, >80 cohorts, and 8 populations. ADVP integrates with NIAGADS Alzheimer's GenomicsDB where investigators can cross-reference other functional evidence.

ADVP is a valuable resource for investigators to quickly and systematically explore high-confidence AD genetic findings and provides insights into population- and tissue-specific AD genetic architecture. ADVP is continually maintained and enhanced by NIAGADS and is freely accessible (https://advp.niagads.org).

1. Introduction

Alzheimer's Disease (AD) is a devastating neurological disorder affecting millions of people worldwide and is the most common cause of dementia [1]. There are no approved drugs that can slow or treat the disease. The disease is complex and highly heritable [2]. The strongest known genetic risk factor for AD is the ε4 allele of the Apolipoprotein E gene (*APOE* ε4) [3,4], but more than one-third of AD cases do not carry any *APOE* ε4 alleles. Large-scale genome-wide association studies (GWASs) have led to the discovery of additional common genetic loci associated with the late-onset AD (LOAD) [5–9]. Yet, the identification of genetic contributors to LOAD remains a challenge as LOAD is likely caused by multiple low penetrance genetic variants [10], with the small sample sizes further complicating the identification of these causal variants.

The Alzheimer's Disease Genetics Consortium (ADGC) was founded in 2009 and funded by National Institute on Aging (NIA), to conduct large sample GWAS to identify genes associated with an increased risk of developing LOAD. ADGC co-founded IGAP (International Genomics of Alzheimer's Project) with three other AD genetics consortia: Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium, the European Alzheimer's Disease Initiative (EADI), and the Genetic and Environmental Risk in Alzheimer's Disease (GERAD) Consortium. IGAP assembled large Caucasian samples for better statistical power and was able to identify 19 genome-wide significant loci in 2013 [11], and five more loci using more than 30,000 samples in 2019 [12].

96 In addition to GWA studies focused on association with disease risk, recently many
97 genetics studies have focused on related phenotypes including neuroimaging
98 biomarkers [13], circulating biomarkers in [14,15], cognitive decline [16,17]
99 neuropathology [18], family history [19]. GWAS on Hispanic, African-American, Asian,
100 and other minority populations also led to new variants not observed in Caucasians [20–
101 22] In order to help investigators better explore the rich and diverse literature of genetic
102 findings, it is important to have a single resource with harmonized, unified, searchable
103 information on identified genetic variants and genes across a variety of AD studies and
104 populations, along with supporting functional genomic evidence.
105
106 To meet this need, we have cataloged genetic association results (both genome-wide
107 significant associations [$p \leq 5 \times 10^{-8}$ by convention] and all other associations highlighted
108 in the main text from all major GWA studies published by ADGC from 2009 to 2019 and
109 other AD GWAS articles identified from the NHGRI/EBI GWAS Catalog (Buniello et al.,
110 2019). Summaries extracted from each of the articles are made publicly available on a
111 continuously updated and freely accessible Alzheimer's Disease Variant Portal (ADVP)
112 (https://advp.niagads.org). To date, ADVP provides the largest, most updated, and
113 comprehensive collection of systematically curated, harmonized, and annotated AD-
114 specific genetic associations. This first release contains information on 6,990 genetic
115 associations, >900 genomic loci curated from >125 AD publications categorized into
116 nine harmonized phenotype categories. All AD associations in ADVP are annotated with
117 genomic and functional information. Comprehensive biological annotations are available
118 via integration with the NIAGADS Alzheimer's Disease Genomics database [24]. ADVP

will serve as an invaluable resource for the research community to explore and decipher the genetic architecture of AD and other neurodegenerative diseases.

2. Methods

An overview of the ADVP study design is shown in **Figure 1**.

2.1 Collection and curation of AD-related GWAS publications (Data collection)

This ADVP V1.0 release consists of curated and harmonized genetic associations from the genome-wide significant and suggestive loci collected from AD genetic studies conducted primarily by the ADGC. All AD GWAS publications by ADGC (2009-2019, http://www.adgenetics.org) and all other AD GWA studies in GWAS catalog [23] (MeSH D000544, curation date: Dec 2019) were included. All the publications (total N=205; ADGC: N=134; Citations from ADGC: N=20; GWAS catalog: N=51) were first screened to identify publications reporting GWAS findings. For each publication, all main genetic associations reported in the main text (table format) were systematically extracted. As the current ADVP release focuses on the major/main findings in each publication/GWA study, we did not extract associations reported in the supplementary tables as they often represent supplemental findings not reaching the same kind of statistical significance as the main associations. In total, we curated the 125 publications which contain GWAS findings in the main text (https://advp.niagads.org/publications). **Supplementary Table S1** provides details on all curated AD publications in ADVP V1.0. Note the ADGC family-based analyses results will be included in the next release.

2.2 Extraction of genetic variants and associations from publications (Data extraction)

We applied the following systematic data extraction and curation procedure for each publication to organize all the extracted variant and association information into a structured tabular format according to the ADVP data schema (see Section "**2.3 Meta-data design**" for details about the columns). In each publication, we identified all the tables in the main text with reported association *p*-values. All the information for these associations was then saved into a standardized template document using the corresponding meta-data schema and the two predefined worksheets: publication meta-data and association meta-data. Lastly, the document is parsed by customized scripts to normalize, validate, annotate, and store the publication, variant, and association data in the relational database [33]. Collected AD variants and association records are further linked (using positional and variant and gene identifier information) with the NIAGADS Alzheimer's Genomics Database [24] which provides the comprehensive annotation and functional genomic information. **Supplementary Note 2** provides details on ADVP architecture and implementation.

2.3 Meta-data schema for systematic curation and harmonization of genetic associations (Meta-data design)

162 **2.3.1 Publication meta-data**

163 Meta-data for all curated publications in ADVP was extracted from PubMed
164 (https://pubmed.ncbi.nlm.nih.gov) using the NCBI EDirect service
165 (https://www.ncbi.nlm.nih.gov/books/NBK179288) with publication PubMed identifiers
166 (PMID) as query keys. For each publication, we record its PMID, PubMed Central
167 identifier (PMCID), first and last authors, journal, and year of publications. We also store
168 the abstract, article URLs, and information on curated/source tables in the Publication
169 meta-data (**Figure 1**).

170

171 **2.3.2 Association meta-data**

172 ADVP association meta-data consists of 28 data fields, of which 19 are extracted
173 directly from the paper contents. The rest are harmonized (based on extracted original
174 information) and programmatically generated fields. Altogether, association meta-data
175 provide 1) variant information (Section "**2.3.2.1 Description of Variants"**); 2)
176 association information (Section "**2.3.2.2 Description of association records"**); and 3)
177 annotation information (Section "**2.4 Annotation of genetic variants and**
178 **associations"**). For a detailed explanation of these curated and harmonized/derived
179 data fields, see **Supplementary Table S2**.

180

181 **2.3.2.1 Description of Variants**

182 Each genetic variant in ADVP is described using dbSNP rsID, genomic coordinates
183 (chromosome:basepair), reference and alternative alleles. Both the information reported
184 in the publication (if available) and those derived from the reference databases such as

185 dbSNP [25] and NIAGADS Alzheimer's Genomics database [24], are included in the
186 variant description. Genomic location in ADVP is currently stored using GRCh37/hg19
187 reference genome build as the majority of GWAS publications conducted analyses
188 using GRCh37/hg19.
189
190 **2.3.2.2 Description of association records**
191 The primary association information was systematically extracted from each source
192 table and recorded as part of the ADVP association record. The extracted information
193 was further recoded and categorized, so that association records are described
194 consistently across publications. For each reported association we first collected a pre-
195 defined set of data attributes commonly reported by genetic association studies (See
196 "Extracted" columns under **Supplementary Table S2**). These include *p*-value and
197 statistics related to the effect size (regression beta coefficients and variance, odds
198 ratios, confidence intervals), reported effect allele and its frequency in the studied
199 population.
200
201 In addition to the information directly extracted from publications, each association in
202 ADVP is described with the nine harmonized meta-information data fields (see
203 **Supplementary Note 1** for more details on each of these fields; field names are
204 denoted with the double quotes below):
205 1. "Record type": association record type.
206 2. "Population": normalized study population information.
207 3. "Cohort": normalized cohort names.

4. “Sample size”: original sample size.
5. “Subset analyzed”: description of the subset of samples used to perform the association analysis.
6. “Phenotype”: the outcome variable (phenotype/trait) of the association analysis.
7. “Association Type”: standardized type of association (disease-risk, eQTL, endophenotype, and others).
8. “Stage”: analysis stage (discovery, validation, replication, or meta- or joint-analysis). Please see (**Supplementary Figure 1, Supplementary Note 1**) for details on how this information was derived.
9. “Imputation”: imputation panel information.

Note, “Population”, “Cohort”, and “Phenotype” information are displayed in ADVP using both the original (reported) and the derived, harmonized data fields.

2.4 Functional genomics evidence for genetic variants and associations (Annotation)

All variants and association in ADVP were systematically annotated with genomic context (closest upstream/downstream genes), genomic element (promoter, UTR, intron, exon, intergenic, repeat), functional impact (variant most severe consequence), and cross-referenced to NIAGADS Alzheimer’s Genomics database [24].

ADVP reports the genomic context of each genetic variant via multiple data fields: 1) “Locus” – records the gene name as reported in the publication; 2) “Nearest gene” – contains the name of the gene closest to the variant and the distance to the gene (in

231 base pairs (bps)) in upstream (+) or downstream (-) orientation. The nearest genes are
232 identified using GENCODE v34 [26] protein-coding gene annotations. For each genetic
233 variant co-localized with one or more genes, both EnsemblID [27] and HGNC [28]
234 symbols for the gene(s) are reported. For each ADVP variant, the co-localized genomic
235 element is reported based on the genomic partition information [29,30].
236

237 **2.5 Variant and association data verification (Quality control steps)**

238 Quality control for the variant and association information in ADVP is carried out at
239 multiple levels:

240 1. We ensured records are not double-counted/re-reported across studies. Each
241 association record in ADVP is uniquely identified by a combination of reported
242 gene/SNP/interaction name, cohort/analyzed subset, association model used,
243 phenotype, and association *p*-value and effect size.
244 2. We cross-checked recorded positional information (chromosome:basepair), rsID,
245 and allele information against reference databases including, dbSNP [25],
246 NIAGADS Alzheimer's Genomics database [24], 1000 Genome data [31] to
247 ensure variant information is correct.
248 3. We identified and removed records solely representing associations annotated
249 by publicly available resources such as GTEx [32].
250

251 **2.6 Population-based analysis of AD associations**

252 To understand the genetic architecture of AD associated loci across populations, we
253 compared their reported effect sizes and frequencies for each locus. In this analysis, we

254 used all association records (from case-control GWAS studies) with complete
255 information on reported allele, effect size (odds ratio), and allele frequency. We then
256 analyzed the four major populations with the most association records (African
257 American, Asian, Caribbean Hispanic, and Caucasian/Non-Hispanic White). Any
258 association records with $p>0.01$ were excluded from analysis. Then for each AD-
259 associated locus (identified using the nearest gene), we selected the association record
260 with the most significant (smallest) *p*-value as a representative record for the locus.
261
262 To perform comparison, we normalized the original (reported) odds ratios to reflect the
263 effect of the minor allele. We further categorized the AD-associated loci as population-
264 specific or shared if they were associated with AD in more than one population under
265 study. We then compared AD-associated loci (both shared and population-specific)
266 across populations based on their normalized effect sizes (odds ratios for minor alleles)
267 and the minor allele frequency.
268

269 **2.7 Functional analysis of AD associations**

270 To perform functional analysis of the variants in ADVP, we evaluated the significance of
271 overlaps between ADVP variants and active enhancer elements across tissues and cell
272 types. We used Roadmap Epigenomics [33] (ChromHMM-determined [34]) and
273 FANTOM5 [35] enhancer sets across 35 tissue/cell type categories. We then ranked
274 individual tissue/cell types based on the degree and significance (odds ratio, Fisher's
275 exact test) of enhancer overlaps in each of the analyzed tissues/cell types.
276

277 # 3. Results

278 In terms of the number of curated AD-related associations and publications, ADVP is
279 more comprehensive than the NHGRI-EBI GWAS catalog [23] (**Table 1**), the premier
280 general catalog of published GWAS results, and more recent than AlzGene [36],
281 another major database of published AD genetic association studies. In order to focus
282 on association findings with the highest confidence, we decided to concentrate on large-
283 scale association studies at the genomic level, with the majority of studies included in
284 ADVP (65%) reporting associations reaching genome-wide significance, a gold
285 standard for human genetic discoveries. Furthermore, ADVP collected extensive meta-
286 data, including consortiums and cohorts, which were not available in the other two
287 databases and are important for relating the results reported across publications.
288 Finally, ADVP provides convenient links for investigators to explore biological
289 significance of the reported variants (e.g., their genomic context, available functional
290 genomic data or other known associations, if any) via an annotation in NIAGADS
291 Alzheimer's Genomics database [24] (**Figure 1**). Following the ADVP curation criteria
292 (see "**Data collection**", **Figure 1**), we first identified and screened 205 AD-related
293 publications from 2009-2019. Out of these, we identified 125 publications with genetic
294 associations reported in the main text tables (N=225 tables). Genetic variant and
295 association data were then systematically extracted (Section "**2.2 Data extraction**"),
296 harmonized ("**2.3 Meta-data design**") (converted into standard variant/association
297 descriptors), annotated ("**2.4 Annotation**"), subjected to quality control steps ("**2.5**
298 **Quality control steps**") and stored in ADVP (**Figure 1**).
299

300 **3.1 ADVP data summary**

301 The ADVP V1.0 release contains high-quality genome-wide and suggestive AD-related
302 genetic associations extracted from GWAS publications. This includes 6,990 genetic
303 associations for variants, genes, and SNP interactions. **Figure 2** shows the distribution
304 of ADVP genetic associations by harmonized meta-information data fields: a) Nine
305 harmonized phenotypes; b) Six harmonized analyses type; c) Population, and d)
306 Cohorts/Consortiums.

307

308 All ADVP association records are uniquely standardized into different categories:

309 1. As shown in **Figure 2A**, ADVP records are associated with nine different
310 phenotype categories, with roughly half of them related to AD diagnosis. 15% of
311 the records are related to fluid biomarkers, 7% with imaging and 6% with
312 cognitive measures.
313 2. With respect to analysis type categories, ADVP includes 3,199 (45.8%)
314 association records reported in disease-risk analyses, of which 1,342 and 934
315 associations are reported by meta- and joint-analyses, respectively. 1,887
316 (26.9%) of the records are related to AD endophenotype and 924 (13.2%) eQTL
317 AD associations (**Figure 2B**).
318 3. ADVP is the first to collect AD genetic associations at SNP level (6,437, 92.1%),
319 gene level (320, 4.5%), as well as SNP and gene interactions (233, 3.3%).
320 4. ADVP records present analyses results from seven populations as well as those
321 from multi-ethnic analyses. ~88% of the records are for Caucasian (**Figure 2C**).

322 Others include African American, Arab, Asian, Caribbean Hispanic, Hispanic and
323 Non-Hispanic Caucasian.
324 5. ADVP records span analyses results published by ADGC using over 80 cohorts
325 (**Figure 2D**), including ADGC, Alzheimer's Disease Neuroimaging Initiative
326 (ADNI), Cohorts for Heart and Aging Research in Genomic Epidemiology
327 (CHARGE) Consortium, European Association of Development Research and
328 Training Institutes (EADI), European Network for Genetic and Genomic
329 Epidemiology (ENGAGE) Consortium, Enhancing NeuroImaging Genetics
330 through Meta-Analysis (ENIGMA) Consortium, The International Genomics of
331 Alzheimer's Project (IGAP) and others. See **Supplementary Table S3** for details
332 on cohorts included in ADVP.
333
334 Furthermore, ADVP provides annotation information for each genetic association
335 (Section "**2.4 Annotation**"). In summary, all the genetic association records in ADVP
336 were represented by >1,800 unique variants (based on genomic position) and >900
337 genomic loci (based on computed normalization). ADVP associations are mostly located
338 in non-coding regions including intronic (52.9%), intergenic (15.2%), and promoter
339 (5.9%) (**Figure 3A**). ADVP records are also cross-referenced to NIAGADS Alzheimer's
340 Genomics database [24]. **Figure 3B** summaries genetic variants in ADVP by functional
341 impact as determined by ADSP functional annotation pipeline [24,37,38] that uses VEP
342 effect predictor with customized ranking to generate most damaging consequence for
343 each variant [38].

344 **3.2 ADVP features – search, browse and visualize**

345 ADVP aims to provide a simple and unified resource to the scientific community,
346 allowing investigators to search and browse AD genetic association information more
347 easily. This is first done by displaying association records using a pre-selected set of
348 most important data fields (Section "**2.3.2.2 Description of association records**").
349 Investigators can further select additional data fields via the column selector (**Figure**
350 **4A**). All records are integrated with the NIAGADS Alzheimer's Genomics database,
351 allowing investigators to explore various kinds of biological annotations (e.g., CADD
352 score (Rentzsch et al., 2019)) and functional genomics evidence, including overlaps
353 with FANTOM5 [35], ENCODE histone modification [40], and gene ontologies from
354 KEGG [41] and UniProt [42].

355

356 The ADVP search interface was designed based on focus group use cases. ADVP
357 provides several ways to search for genetic association records:

358 1. By publication – investigators can quickly identify and retrieve all association
359 records curated by ADVP for a particular study using PMID, PMCID, first or last
360 author names, year of publication or article title
361 (https://advp.niagads.org/publications).
362 2. By variant or gene of interest – investigators can search for the variant
363 (https://advp.niagads.org/variants) or gene (https://advp.niagads.org/genes) of
364 interest and browse all the associated ADVP records. Additionally, investigators
365 can easily discover top variants or a gene with most association records or most

366 publications via the summary counts for association records and papers (**Figure**
367 **4B, 4C**).
368 3. By region of interest – investigators can search and retrieve all genetic
369 associations within the genomic regions of interest
370 (https://advp.niagads.org/search).
371 4. By integrative genome-wide plots – investigators can navigate the landscape of
372 AD genetics associations using the interactive chromosome ideogram
373 (https://advp.niagads.org/ideogram, **Figure 4D**) or interactive
374 population/phenotype variant viewer (https://advp.niagads.org/plot, **Figure 4E**).
375 Additionally, for each variant or gene, users can view the biological annotations and
376 functional evidence (e.g., 1000 Genomes project [31], dnSNP [25], GTEx [32],
377 ENCODE [40] and others) via the NIAGADS Alzheimer's Genomics database [24]
378 (**Figure 4F**).
379

380 **3.3 ADVP use cases**

381 ADVP is designed for various use cases in mind. First, ADVP can serve as a point of
382 entry for investigators to explore the AD genetics literature. They can browse through
383 variant and gene records, identify top associated loci for particular populations and
384 phenotypes, or inspect top GWAS associations in the gene or genomic region of
385 interest. Second, investigators can use ADVP to check their association analysis
386 findings. They can further restrict the comparison by focusing on results from a specific
387 population, cohort, or by comparing the strength of associations via *p*-values or
388 phenotypes. Lastly, investigators can use ADVP to check if their findings have

389 functional support from eQTL or other functional evidence collected in the NIAGADS
390 Alzheimer's genomics database (**Figure 4F**).
391

392 **3.4. Genetic architecture of AD-associated loci across populations**

393 To show the diversity and breadth of ADVP data, we performed population-based
394 analysis of AD associations in ADVP (Section **"2.6 Population-based analysis of AD**
395 **associations"**). Across four major populations (African American, Asian, Caribbean
396 Hispanic, Caucasian/Non-Hispanic white) with the most association records, 91 loci
397 (Section "**2.6 Population-based analysis of AD associations"**) were identified in any
398 of these 4 populations, whereas 10 of them were found in two or more populations,
399 including *BIN1*, *CD33*, *PICALM*, *SORL1*, and *ABCA7*. The majority of AD loci
400 (81/91=89%) were population-specific, i.e. found in only one population. This could
401 partially be explained by the underlying genetic differences across populations, but
402 could also be contributed by variability in GWAS sample sizes across
403 studies/populations, which could lead to the observed differences in association
404 strength and heterogeneity of loci identified in each population. Across the four
405 populations, the corresponding top SNP (Section "**2.6 Population-based analysis of**
406 **AD associations"**), effect size and allele frequency on all these 91 loci are available in
407 **Supplementary Table S4**.
408

409 We next explored the effect size and allele frequency of all AD-associated loci that are
410 found in any populations (**Figure 5A**), or those that are found in two or more
411 populations (shared AD loci) (**Figure 5B**).

412

413 As can be seen from **Figure 5**, ADVP captures reported AD-associated loci across
414 many populations (**Figure 5A**; only non-*APOE* loci from 4 populations are shown).
415 ADVP contains both population-specific AD loci and loci that are shared across
416 populations. As shown in **Figure 5B**, the shared loci tend to preserve their risk (e.g.,
417 *ABCA7* [43]) and protective roles (e.g., *PICALM* [44]) .
418

419 On the other hand, as shown in **Figure 5A**, common loci tend to exert smaller effects
420 compared to population-specific loci, yet these effects of the common loci vary across
421 populations (**Figure 5B**) (i.e. are population-specific).
422

423 **3.5. Functional analysis of ADVP variants**

424 We next investigated the functional impact of ADVP variants. To do so, we analyzed all
425 ADVP variants that are associated with AD/ADRD (excluding eQTLs) in the Caucasian
426 or non-Hispanic White populations. A total of 1,675 ADVP variants met these criteria
427 and were analyzed.
428

429 First, to determine the potential causal genes for these variants, we asked if these
430 variants regulate any genes in any AMP-AD [45] eQTL data [46] obtained from three
431 different brain regions (dorsolateral prefrontal cortex, cerebellum and temporal cortex).
432 Please see this publication [46] for details of how these data eQTL was harmonized and
433 processed.
434

435 31% of the analyzed ADVP variants were identified as significant eQTLs in at least one
436 of the three AMP-AD eQTL datasets (FDR<0.01), and 32% among these were eQTLs in
437 all three brain regions. Altogether, these variants targeted 130 genes (including HLA
438 region), of which 31 were also the nearest genes reported in ADVP. These target genes
439 (e.g., *ACE, PVR*) were enriched in cell junction organization [47], and acetyltransferase
440 activity (cholinergic system) [48], which recapitulated some of the molecular and cellular
441 mechanisms underlying the pathogenesis of AD.
442
443 Second, we analyzed and ranked relevant tissue categories implicated by ADVP
444 variants. To do so, we quantified the significance and enrichment of tissue-specific
445 enhancer overlaps with ADVP variants (Section "**2.7 Functional analysis of AD**
446 **associations"**). The ADVP variants were enriched in regulatory elements profiled by
447 FANTOM5 and Roadmap Epigenomics (ChromHMM). Top tissues enriched in overlaps
448 between ADVP variants and Roadmap enhancers included AD-relevant blood
449 (OR=3.7), digestive (OR=3.5), brain (OR=2.8), and skeletal (OR=2.6) tissue categories.
450 The overlaps between ADVP variants and enhancers were shown to be enriched in
451 tissues known to be related to AD in various ways [49–55]. For instance, the implicated
452 immunity-related blood category is in line with recent work highlighting the role of
453 neuroinflammation in AD pathogenesis and etiology [49,55]. Digestive is related to the
454 gut microbiome, which can be linked to AD behavior in mice [56]. The implicated
455 skeletal category has also been previously linked with brain atrophy in AD [51].
456

457 In summary, analyses of genetic associations in ADVP revealed potential functional
458 roles of the AD variants in relevant tissue/cell type context, and recapitulated some of
459 the known regulatory mechanisms underlying AD pathogenesis.
460

461 # 4. Discussion

462 Here, we present ADVP, a portal to search, browse and visualize the largest collection
463 of systematically curated, harmonized, and annotated AD-specific genetic variants and
464 associations (~7,000 genetic associations in the current V1.0 release, November 2020).
465 Among the main distinctive features of ADVP is the uniqueness of reporting harmonized
466 AD variant and association information (standardized meta-table curation schema),
467 integration with the genomic annotation, and functional information (NIAGADS
468 Alzheimer's Genomics database [24]), as well as extensive cohort/consortium level
469 information.
470

471 ADVP uniquely includes associations at SNP, gene, and interaction levels and contains
472 curated phenotypes not limited to disease risk, but also includes endophenotypes, fluid
473 biomarkers, imaging, neuropathology, and other phenotypes. Moreover, ADVP curates
474 and records AD and ADRD eQTL association findings (**Figure 2B**).
475

476 In addition to the standard *p*-values and effect sizes reported for association records,
477 ADVP puts particular emphasis on harmonizing meta-data curated from the
478 publications. Both the curated and derived columns are stored in the database. These
479 include phenotype, association type, standardized gene names, study information

480 (population, cohort, sample size, subset analyzed), and details of analyses (analyses
481 type, imputation) (**Figure 4A**). All these columns enable the investigators to interpret,
482 compare and view these records at different levels: phenotype (**Figure 2A**), population
483 (**Figure 2C**), cohort (**Figure 2D**), to name a few.
484
485 All ADVP records are annotated with the genomic context (upstream/downstream
486 genes, and their distances) and their co-localized genomic element (**Figure 3**). They are
487 also cross-referenced with NIAGADS Alzheimer's Genomics DB [24], providing other
488 genomic annotation and functional genomic information. The standardized, structured
489 design of ADVP association data allows systematic integration with other genetic,
490 genomics, and molecular databases.
491
492 Population-based and functional analyses of AD associations revealed the genetic
493 architecture of AD-associated loci and points to tissue-specific regulatory mechanisms
494 for AD. However, variability in GWAS sample sizes may contribute to the observed
495 differences in associations and loci across different populations. Broadening the ADVP
496 coverage of population groups, as well as expanding functional data types and
497 coverage will provide further insights in complex genetic architecture and biology
498 underlying AD.
499
500 Lastly, we made substantial efforts to ensure high-quality of ADVP data contents. First,
501 quality control at multiple levels is performed (**Figure 1**, Section "**2.5 Quality control**
502 **steps**") to ensure the uniqueness of included genetic associations (no double counting /

503 re-reporting of associations). Besides, variant information in ADVP has been cross-
504 checked against other reference databases such as dbSNP.
505
506 ADVP will continuously be updated with versioned releases every six months. New
507 publications on AD-related GWASs and corresponding associations will be added in an
508 ongoing manner.
509
510 In the future, ADVP data collections will consist of a broader range of genetic results:
511 1. AD whole-genome/whole-exome sequencing analyses
512 2. AD xQTL associations, where x = protein, methylation, epigenetics marks, or
513 other molecular traits Other genetic variant types, such as insertions/deletions
514 (indel), copy number variations (CNV), or structural variations (SV) as they
515 become available
516 3. AD related dementias (ADRD) and neurodegenerative disorders
517
518 Future ADVP functionality will include further collection and addition of functional
519 genomic evidence supporting genetic associations.
520
521 To conclude, ADVP contains the largest collection of systematically curated,
522 harmonized, and annotated literature-derived variants for AD to the best of our
523 knowledge. The extensive and unique features in ADVP allow investigators to easily
524 access, interpret, compare, and visualize the vast collection of AD genetics findings.

5. Availability

All AD variant and association information is available through ADVP website (https://advp.niagads.org). The code for processing reported variant and association data is available upon request.

6. Acknowledgement

The authors thank Laura Cantwell, Lauren Kleidermacher, and Mitchell Tang for their contributions at various stages of this work. This work was supported by the National Institute on Aging [U24-AG041689, U54-AG052427, U01-AG032984, U01AG058654]; Biomarkers Across Neurodegenerative Diseases (BAND 3) (award number 18062), co-funded by Michael J Fox Foundation, Alzheimer's Association, Alzheimer's Research UK and the Weston Brain institute.

7. Figures



Figure 1. ADVP study design. AD GWAS publications are first collected (Section **"2.1 Data collection"**), genetic variant and association data are then systematically extracted (Section "**2.2 Data extraction**"), harmonized (Section "**2.3 Meta-data design**"), annotated (Section "**2.4 Annotation**"), subjected to quality control steps (Section "**2.5 Quality control steps**") and stored into ADVP.



Figure 2: Summary of genetic association records in ADVP by **A**) Phenotype, **B**) Association type, **C**) Population, and **D**) Cohort/Consortium.



Figure 3: Summary of ADVP association records by genome annotation and most-significant functional consequence. **A)** Genomic localization of ADVP variants within mRNA, lncRNA, and repeat elements. Shown are proportion (%) of variants in each genomic element category; **B)** Most-significant predicted variant impact. Impact for variants is determined using ADSP functional annotation pipeline [38,57] and is provided by NIAGADS Alzheimer's Genomics database [24]. The consequence for a variant is predicted and ranked based on multiple criteria including genomic location of a variant, genes, transcripts and protein sequences, biological type of transcript, transcript support level and other factors.

573 A)

Showing 1 - 12 of 12 records

Reset Filters | Show/Hide Columns

- Reported gene
- Interactions
- Population
- Population (detailed)
- Cohort
- Cohort (detailed)
- Sample size

Pubmed ID	Record type	SNP	Coordinates	Locus	Population	Cohort	Sample size	Subset Analyzed	Phenoty	
30820047	SNP-based	rs75932628	6:41129252	TREM2	Non-Hispanic Caucasian	ADGC, CHARGE, EADI, GERAD	63,926	All	AD	
30820047	SNP-based	rs75932628	6:41129252	TREM2	Non-Hispanic Caucasian	ADGC, CHARGE, EADI, GERAD	82,771	All	AD	
23150908	SNP-based	rs75932628	6:41129252	TREM2	Caucasian	Cohort from Europe	113,600	All	AD	
23150908	SNP-based	rs75932628	6:41129252	TREM2	Caucasian	Cohort from Europe	12,438	All	AD	
23150908	SNP-based	rs75932628	6:41129252	TREM2	Caucasian	Cohort from Europe	4,786	All	AD	Disease risk
28714976	SNP-based	rs143332484	6:41129207	TREM2	Caucasian	CHARGE, EADI, GERAD	3,968	All	AD	Disease risk
28714976	SNP-based	rs75932628	6:41129252	TREM2	Caucasian	ADGC	14,884	All	AD	Disease risk
28714976	SNP-based	rs75932628	6:41129252	TREM2	Caucasian	ADGC, CHARGE, EADI, GERAD	30,018	All	AD	Disease risk
28714976	SNP-based	rs143332484	6:41129207	TREM2	Caucasian	ADGC, CHARGE, EADI, GERAD	33,786	All	AD	Disease risk
28714976	SNP-based	rs75932628	6:41129252	TREM2	Caucasian	CHARGE, EADI, GERAD	35,831	All	AD	Disease risk
28714976	SNP-based	rs143332484	6:41129207	TREM2	Caucasian	ADGC, CHARGE, EADI, GERAD	53,042	All	AD	Disease risk
28714976	SNP-based	rs75932628	6:41129252	TREM2	Caucasian	ADGC, CHARGE, EADI, GERAD	80,733	All	AD	Disease risk

574 « ‹ Page 1 of 1 › » Show 20 records

575 B)

Variants

Sort by frequency

Showing 1 - 10 of 1826 records

Variant	Reported gene(s)	Location	View in Genomics	Association records	Papers
rs3865444	CD33	chr19:51727962	View	39	16
rs11136000	CLU; CUGBP2; PICALM	chr8:27464519	View	60	15
rs2075650	APOC1, APOC4, APOE, PV	chr19:45395619	View	43	15
rs11218343	PICALM; SORL1	chr11:121435587	View	27	13
rs3851179	CUGBP2; PICALM	chr11:85868640	View	50	13
rs6656401	CR1,CR2; CR1; CR1L; CR2	chr1:207692049	View	76	12
rs3818361	CR1; CUGBP2	chr1:207784968	View	43	11
rs157580	PVRL2, TOMM40; TOMM4	chr19:45395266	View	15	10
rs1476679	PILRA, PILRB; GATS; MSX:	chr7:100004446	View	131	9
rs405509	APOE, TOMM40; APOE	chr19:45408836	View	28	9

576 « ‹ Page 1 of 183 › » Show 10 records

577

578

579

580

581

582

C)

Genes

Sort by frequency

Showing 1 - 10 of 952 records

Gene Name	Ensembl ID	View in Genomics DB	Association records	Papers
CLU	ENSG00000120885	View	179	29
BIN1	ENSG00000136717	View	138	28
CR1	ENSG00000203710	View	170	26
PICALM	ENSG00000073921	View	152	22
APOE	ENSG00000130203	View	99	22
TOMM40	ENSG00000130204	View	136	19
ABCA7	ENSG00000064687	View	82	18
SORL1	ENSG00000137642	View	164	17
EPHA1	ENSG00000146904	View	40	17
CD33	ENSG00000105383	View	40	16

« ‹ Page 1 of 96 › » Show 10 records

D)

Chromosome ideogram

To browse variants, click on a particular chromosome for enlarged view of the chromosome and associated genomic loci and/or click on genomic locus marker (red rectangle) to display variant table for a particular genomic locus. When in chromosme view, click on the chromosome again, to go back to the ideogram.



Legend
ADVP genome-wide significant variants (p<5e-8)

606 E)


Variant viewer by Population/Phenotype
Switch between 'Population', 'Phenotype' to view variants across populations, and phenotypes.
To highlight variants for a particular population/phenotype, click on the corresponding population/phenotype in the legend (clicking on a legend item will toggle between highlight and normal view).
Population
Phenotype
Select Effect size axis:
Log
Linear
Log2 of Effect size (OR), Absolute value
Minor allele frequency
African American
Asian
Caribbean Hispanic
Caucasian
Non-Hispanic Caucasian
Transethnic

623 F)

6:41129207:C:T (rs143332484)
CCACAAGTTGTGCGTGCTGACCACAC/TGCTGGCATGGGCCCTTCTCTCCCAG
single-nucleotide variant
Add to Basket
Add to Favorites
ADSP Variant WES WGS
WGS Filter Status: PASS: pass in both GATK and ATLAS
WES Filter Status: PASS: pass in both GATK and ATLAS
More information: dbSNP Ensembl GTEx ExAC
Contents
Genomic Context
Population Frequencies
Trait Associations
Classification/Predicted Effects
Functional Genomics

624

625 **Figure 4** – ADVP interface. **A)** Association records table. The displayed information can
626 be customized via column/field selector and filtered using provided text and data filters;
627 **B)** Top variants curated in ADVP. Variants are displayed according to the number of
628 reporting publications by default; association records for variants and variant-related
629 publications can be quickly accessed; **C)** Top genes curated in ADVP. Genes are
630 ordered by the number of reporting publications by default; gene-related association
631 records and publications can be quickly accessed; **D)** Interactive chromosome
632 ideogram-based view of association data; **E)** Interactive variant viewer by population
633 and phenotype. Variants are arranged by their effect size (odds ratio; Y-axis) and allele
634 frequency (X-axis) and color-coded by population and phenotype; **F)** Integration with
635 NIAGADS AD Genomics database [24] providing additional biological information and
636 functional evidence (red rectangles).

637

638

639

640

641

642

643

644

645

646

A)


African American
Asian
Caribbean Hispanic
Caucasian
Odds Ratio
3.0
1.0
0.3
0.01
0.03
0.10
0.30
Minor Allele Frequency
COBL
SLC10A2
MSX2
SLC4A1AP
ARHGAP45
BIN1
IGLON5
TAS2R60
CYP27C1
TBX3
STK24
PICALMENOX1
ZC3H3
HAS2
PALM2AKAP2
RIN3
CR1
BIN1
MARK4
CLU
EED
SORL1
EFCAB14
GATA3
CCDC83
CACNA2D3
CD33
FBXL7
REM2
MTHFD1L
TRIP4
HID1
NECTIN2
RDH13
LTBP2
BCAM
BIN1
CASS4
SORL1
CDH9
FST
DSG2
Population−specific
Shared

651 **B)**



652

653

654 **Figure 5**. ADVP catalogs AD genetic associations across 8 populations (>80 cohorts).

655 AD-associated loci (non-*APOE*) for four major populations (African American, Asian,

656 Caribbean Hispanic, Caucasian/Non-Hispanic White) are shown in this figure. For each

657 locus, shown are the allele frequency and odds ratio for the most significant variant

658 located with the locus. ADVP data captures the diversity and population-specificity of

659 AD-associated loci. **A)** Shown are loci associated with AD in each of the major

660 populations (shared loci are colored black, population-specific loci are shown in blue).

661 **B)** Shown are shared AD loci reported in two or more major populations.

662 # 8. Tables

663 **Table 1**: Comparison between ADVP and existing AD genetics database (AlzGene and

664 GWAS Catalog).

Features	**AlzGene** [36]	**GWAS Catalog** [23]	**ADVP**
Focus on AD	Yes	No	Yes
Types of genetic associations recorded / included	Variant only	Variant only	Variant, Gene, SNP-SNP and gene-gene interactions
Included associations (*p*-value cutoff)	Genome-wide significant only ($<5*10^{-8}$)	Genome-wide significant only ($<5*10^{-8}$)	Both genome-wide significant and suggestive associations
Number of curated AD GWAS publications (publication years)	41 (1998-2011)	69 (2007-current)	Initial set: 205; Curated set: 125 (2009-current)
Number of curated records/associations	264 genes	1,532 records (1,155 variants)	6,605 AD, 6,990 total association records (1,825 variants)
Genomic and functional genomic annotations	No	No	NIAGADS Alzheimer's Genomics database [24] annotations
Detailed / extensive meta-data	Population, cohort, sample size, phenotype	Population, sample size, stage, phenotype	Record type (SNP/gene-based), population, cohort, sample size, subset analyzed, phenotype, association type, stage, imputation
Last update date	2011	2021	2021

665

666

667

668

669 # 9. References

670 [1] Association A. 2019 Alzheimer's disease facts and figures. Alzheimer's Dement
671 2019;15:321–87. https://doi.org/doi:10.1016/j.jalz.2019.01.010.

672 [2] Gatz M, Pedersen NL, Berg S, Johansson B, Johansson K, Mortimer JA, et al.
673 Heritability for Alzheimer's disease: The study of dementia in Swedish twins.
674 Journals Gerontol - Ser A Biol Sci Med Sci 1997;52.
675 https://doi.org/10.1093/gerona/52A.2.M117.

676 [3] Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small
677 GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's
678 disease in late onset families. Science 1993;261:921–3.
679 https://doi.org/10.1126/science.8346443.

680 [4] Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, Combarros O, et al.
681 APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol
682 Psychiatry 2011;16:903–7.

683 [5] Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al.
684 Genome-wide association study identifies variants at CLU and CR1 associated
685 with Alzheimer's disease. Nat Genet 2009;41:1094–9.

686 [6] Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al.
687 Genome-wide association study identifies variants at CLU and PICALM
688 associated with Alzheimer's disease. Nat Genet 2009;41:1088–93.

689 [7] Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, et
690 al. Genome-wide analysis of genetic loci associated with Alzheimer disease.
691 JAMA 2010;303:1832–40.

692 [8] Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al.
693 Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are
694 associated with Alzheimer's disease. Nat Genet 2011;43:429–35.

695 [9] Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, et al. Common
696 variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-
697 onset Alzheimer's disease. Nat Genet 2011;43:436–41.

698 [10] Naj AC, Schellenberg GD. Genomic variants, genes, and pathways of Alzheimer's
699 disease: An overview. Am J Med Genet B Neuropsychiatr Genet 2017;174:5–26.

700 [11] Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al.
701 Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for
702 Alzheimer's disease. Nat Genet 2013;45:1452–8.

703 [12] Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al. Genetic
704 meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and
705 implicates Ab, tau, immunity and lipid processing. Nat Genet 2019;51:414–30.

706 [13] Biffi A, Anderson CD, Desikan RS, Sabuncu M, Cortellini L, Schmansky N, et al.
707 Genetic variation and neuroimaging measures in Alzheimer disease. Arch Neurol
708 2010;67:677–85.

709 [14] Kauwe JS, Bailey MH, Ridge PG, Perry R, Wadsworth ME, Hoyt KL, et al.
710 Genome-wide association study of CSF levels of 59 alzheimer's disease
711 candidate proteins: significant associations with proteins involved in amyloid
712 processing and inflammation. PLoS Genet 2014;10:e1004758.

713 [15] Cruchaga C, Kauwe JS, Harari O, Jin SC, Cai Y, Karch CM, et al. GWAS of
714 cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease.
715 Neuron 2013;78:256–68.

716 [16] Barral S, Bird T, Goate A, Farlow MR, Diaz-Arrastia R, Bennett DA, et al.
717 Genotype patterns at PICALM, CR1, BIN1, CLU, and APOE genes are associated
718 with episodic memory. Neurology 2012;78:1464–71.

719 [17] Barral S, Cosentino S, Christensen K, Newman AB, Perls TT, Province MA, et al.
720 Common genetic variants on 6q24 associated with exceptional episodic memory
721 performance in the elderly. JAMA Neurol 2014;71:1514–9.

722 [18] Beecham GW, Hamilton K, Naj AC, Martin ER, Huentelman M, Myers AJ, et al.
723 Genome-wide association meta-analysis of neuropathologic features of
724 Alzheimer's disease and related dementias. PLoS Genet 2014;10:e1004606.

725 [19] Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, et al.
726 Genome-wide meta-analysis identifies new loci and functional pathways
727 influencing Alzheimer's disease risk. Nat Genet 2019;51:404–13.

728 [20] Cukier HN, Kunkle BW, Vardarajan BN, Rolati S, Hamilton-Nelson KL, Kohli MA,
729 et al. ABCA7 frameshift deletion associated with Alzheimer disease in African

730 Americans. Neurol Genet 2016;2:e79.

731 [21] Mez J, Chung J, Jun G, Kriegel J, Bourlas AP, Sherva R, et al. Two novel loci,
732 COBL and SLC10A2, for Alzheimer's disease in African Americans. Alzheimers
733 Dement 2017;13:119–29.

734 [22] Hirano A, Ohara T, Takahashi A, Aoki M, Fuyuno Y, Ashikawa K, et al. A
735 genome-wide association study of late-onset Alzheimer's disease in a Japanese
736 population. Psychiatr Genet 2015;25:139–46.

737 [23] Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C, et al.
738 The NHGRI-EBI GWAS Catalog of published genome-wide association studies,
739 targeted arrays and summary statistics 2019. Nucleic Acids Res 2019;47:D1005–
740 12.

741 [24] Greenfest-Allen E, Klamann C, Gangadharan P, Kuzma A, Leung YY, Valladares
742 O, et al. NIAGADS Alzheimer's GenomicsDB: A resource for exploring
743 Alzheimer's Disease genetic and genomic knowledge 2020.
744 https://doi.org/https://doi.org/10.1101/2020.09.23.310276.

745 [25] Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP:
746 the NCBI database of genetic variation. Nucleic Acids Res 2001;29:308–11.

747 [26] Frankish A, Diekhans M, Ferreira AM, Johnson R, Jungreis I, Loveland J, et al.
748 GENCODE reference annotation for the human and mouse genomes. Nucleic
749 Acids Res 2019;47:D766--D773.

750 [27] Yates AD, Achuthan P, Akanni W, Allen J, Allen J, Alvarez-Jarreta J, et al.
751 Ensembl 2020. Nucleic Acids Res 2020;48:D682--D688.

752 [28] Braschi B, Denny P, Gray K, Jones T, Seal R, Tweedie S, et al. Genenames.org:
753 The HGNC and VGNC resources in 2019. Nucleic Acids Res 2019;47:D786--
754 D792. https://doi.org/10.1093/nar/gky930.

755 [29] Amlie-Wolf A, Tang M, Mlynarski EE, Kuksa PP, Valladares O, Katanic Z, et al.
756 INFERNO: inferring the molecular mechanisms of noncoding genetic variants.
757 Nucleic Acids Res 2018;46:8740–53. https://doi.org/10.1093/nar/gky686.

758 [30] Kuksa PP, Lee C-Y, Amlie-Wolf A, Gangadharan P, Mlynarski EE, Chou Y-F, et
759 al. SparkINFERNO: A scalable high-throughput pipeline for inferring molecular
760 mechanisms of non-coding genetic variants. Bioinformatics 2020.
761 https://doi.org/10.1093/bioinformatics/btaa246.

762 [31] Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, et al. A
763 global reference for human genetic variation. Nature 2015;526:68–74.

764 [32] Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, et al. The
765 Genotype-Tissue Expression (GTEx) project. Nat Genet 2013;45:580–5.
766 https://doi.org/10.1038/ng.2653.

767 [33] Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, Heravi-Moussavi A, et al.
768 Integrative analysis of 111 reference human epigenomes. Nature 2015;518:317–
769 30. https://doi.org/10.1038/nature14248.

770 [34] Ernst J, Kellis M. ChromHMM: Automating chromatin-state discovery and
771 characterization. Nat Methods 2012;9:215–6. https://doi.org/10.1038/nmeth.1906.

772 [35] Andersson R, Gebhard C, Miguel-Escalada I, Hoof I, Bornholdt J, Boyd M, et al.
773 An atlas of active enhancers across human cell types and tissues. Nature
774 2014;507:455–61. https://doi.org/10.1038/nature12787.

775 [36] Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-
776 analyses of Alzheimer disease genetic association studies: the AlzGene
777 database. Nat Genet 2007;39:17–23.

778 [37] Cingolani P, Platts A, Wang LL, Coon M, Nguyen T, Wang L, et al. A program for
779 annotating and predicting the effects of single nucleotide polymorphisms, SnpEff:
780 SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly
781 (Austin) 2012;6:80–92. https://doi.org/10.4161/fly.19695.

782 [38] Butkiewicz M, Blue EE, Leung YY, Jian X, Marcora E, Renton AE, et al.
783 Functional annotation of genomic variants in studies of late-onset Alzheimer's
784 disease. Bioinformatics 2018;34:2724–31.
785 https://doi.org/10.1093/bioinformatics/bty177.

786 [39] Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: Predicting the
787 deleteriousness of variants throughout the human genome. Nucleic Acids Res
788 2019;47:D886--D894. https://doi.org/10.1093/nar/gky1016.

789 [40] Dunham I, Kundaje A, Aldred SF, Collins PJ, Davis CA, Doyle F, et al. An
790 integrated encyclopedia of DNA elements in the human genome. Nature

791 2012;489:57–74. https://doi.org/10.1038/nature11247.

792 [41] Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M. KEGG as a
793 reference resource for gene and protein annotation. Nucleic Acids Res
794 2016;44:D457--D462. https://doi.org/10.1093/nar/gkv1070.

795 [42] Huntley RP, Sawford T, Mutowo-Meullenet P, Shypitsyna A, Bonilla C, Martin MJ,
796 et al. The GOA database: Gene Ontology annotation updates for 2015. Nucleic
797 Acids Res 2015;43:D1057--D1063. https://doi.org/10.1093/nar/gku1113.

798 [43] Reitz C, Jun G, Naj A, Rajbhandary R, Vardarajan BN, Wang L-S, et al. Variants
799 in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4,and the risk
800 of late-onset Alzheimer disease in African Americans. JAMA 2013;309:1483–92.
801 https://doi.org/10.1001/jama.2013.2973.

802 [44] Thomas RS, Henson A, Gerrish A, Jones L, Williams J, Kidd EJ. Decreasing the
803 expression of PICALM reduces endocytosis and the activity of β-secretase:
804 implications for Alzheimer's disease. BMC Neurosci 2016;17:50.
805 https://doi.org/10.1186/s12868-016-0288-1.

806 [45] Hodes RJ, Buckholtz N. Accelerating Medicines Partnership: Alzheimer's Disease
807 (AMP-AD) Knowledge Portal Aids Alzheimer's Drug Discovery through Open Data
808 Sharing. Expert Opin Ther Targets 2016;20:389–91.
809 https://doi.org/10.1517/14728222.2016.1135132.

810 [46] Sieberts SK, Perumal TM, Carrasquillo MM, Allen M, Reddy JS, Hoffman GE, et
811 al. Large eQTL meta-analysis reveals differing patterns between cerebral cortical

812 and cerebellar brain regions. Sci Data 2020;7:340.
813 https://doi.org/10.1038/s41597-020-00642-8.

814 [47] Reymond N, Imbert A-M, Devilard E, Fabre S, Chabannon C, Xerri L, et al.
815 DNAM-1 and PVR regulate monocyte migration through endothelial junctions. J
816 Exp Med 2004;199:1331–41. https://doi.org/10.1084/jem.20032206.

817 [48] Kehoe PG. The Coming of Age of the Angiotensin Hypothesis in Alzheimer's
818 Disease: Progress Toward Disease Prevention and Treatment? J Alzheimers Dis
819 2018;62:1443–66. https://doi.org/10.3233/JAD-171119.

820 [49] Heneka MT, Golenbock DT, Latz E. Innate immunity in Alzheimer's disease. Nat
821 Immunol 2015;16:229–36. https://doi.org/10.1038/ni.3102.

822 [50] Jiang C, Li G, Huang P, Liu Z, Zhao B. The Gut Microbiota and Alzheimer's
823 Disease. J Alzheimers Dis 2017;58:1–15. https://doi.org/10.3233/JAD-161141.

824 [51] Loskutova N, Honea RA, Vidoni ED, Brooks WM, Burns JM. Bone density and
825 brain atrophy in early Alzheimer's disease. J Alzheimers Dis 2009;18:777–85.
826 https://doi.org/10.3233/JAD-2009-1185.

827 [52] Wan Y-W, Al-Ouran R, Mangleburg CG, Perumal TM, Lee T V, Allison K, et al.
828 Meta-Analysis of the Alzheimer's Disease Human Brain Transcriptome and
829 Functional Dissection in Mouse Models. Cell Rep 2020;32:107908.
830 https://doi.org/10.1016/j.celrep.2020.107908.

831 [53] Amlie-Wolf A, Tang M, Way J, Dombroski B, Jiang M, Vrettos N, et al. Inferring

832 the Molecular Mechanisms of Noncoding Alzheimer's Disease-Associated
833 Genetic Variants. J Alzheimers Dis 2019;72:301–18. https://doi.org/10.3233/JAD-
834 190568.

835 [54] Kikuchi M, Hara N, Hasegawa M, Miyashita A, Kuwano R, Ikeuchi T, et al.
836 Enhancer variants associated with Alzheimer's disease affect gene expression via
837 chromatin looping. BMC Med Genomics 2019;12:128.
838 https://doi.org/10.1186/s12920-019-0574-8.

839 [55] Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J,
840 et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-
841 mediated innate immunity in Alzheimer's disease. Nat Genet 2017;49:1373–84.
842 https://doi.org/10.1038/ng.3916.

843 [56] Kundu P, Torres ERS, Stagaman K, Kasschau K, Okhovat M, Holden S, et al.
844 Integrated analysis of behavioral, epigenetic, and gut microbiome analyses in
845 AppNL-G-F, AppNL-F, and wild type mice. Sci Rep 2021;11:4678.
846 https://doi.org/10.1038/s41598-021-83851-4.

847 [57] McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann A, et al. The
848 Ensembl Variant Effect Predictor. Genome Biol 2016;17.
849 https://doi.org/10.1186/s13059-016-0974-4.

850